Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression.

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals - 1 Nov 2017

Wang Xiaojiang, Meng Qinghua, Wang Chuanhai, Li Fajiu, Zhu Zhiyang, Liu Shuang, Shi Yi, Huang Jie, Chen Shi, Li Chenghong

Abstract excerpt

PURPOSE: Using transrenal DNA to detect KRAS mutations in non-small cell lung cancer (NSCLC), the study addressed the clinical impact for longitudinal monitoring and prognostic value for disease outcome. METHODS: Digital droplet PCR was used to detect the mutant DNA. A total of 200 NSCLC patients were recruited with varying molecular profiles. To ascertain the specificity of transrenal DNA to accurately profile...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to KRAS gene

Share to Lung Neoplasms

Share to Mutation

Share to Polymerase Chain Reaction

Share to Proto-Oncogene Proteins p21(ras)

Share to Survival Rate

Source

Identifiers

PMID: 27998182
DOI: 10.1080/1354750X.2016.1269202

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression.PMID 27998182Read ↗

Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.Semantic proximity Read ↗

Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients.Semantic proximity Read ↗

Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy.Semantic proximity Read ↗

Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor mutation testing: From conventional to real-time diagnosis of lung cancer.Semantic proximity Read ↗

Detection of KRAS mutations in circulating tumour DNA from plasma and urine of patients with colorectal cancer.Semantic proximity Read ↗

Comparative Liquid Biopsy Testing for KRAS Mutations From Plasma Cell-Free DNA (cfDNA) and Extracellular Vesicles in Lung Adenocarcinoma.Semantic proximity Read ↗

Non-invasive profiling of KRAS mutations in lung cancer using droplet digital polymerase chain reaction.Semantic proximity Read ↗

Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.Semantic proximity Read ↗

Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCRSemantic proximity Read ↗

Differences in the genomic profiles of cell‐free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLCSemantic proximity Read ↗

Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.